Cell and gene therapies are changing lives. They engineer patients’ cells or DNA to create personalized therapies, unlocking long-lasting or even curative treatments for diseases with high unmet needs ...

During cell therapy development, some scientists are moving away from viral transfection and toward electroporation for introducing CRISPR systems and other nucleic acid payloads. As electroporation ...

MADISON, Wis., Aug. 11, 2021 /PRNewswire/ -- Mirus Bio, an innovator in transfection technologies, today announces the launch of the TransIT® VirusGEN® GMP product line. This expansion to the existing ...

Gene therapy involves the transfer of genetically modified materials into a patient's cells to correct abnormal genes associated with diseases (Sun, 2017). Recent advancements in gene therapy have ...

A mathematical model could help reduce the experimental effort needed to develop production processes for gene therapies. The digital twin, developed by a team at University College London (UCL) in ...

Advances company’s ambition to provide fully integrated and comprehensive solution for viral vector manufacturing Mirus Bio’s leading GMP transfection reagents complement company’s upstream ...

Efficient viral vector production is essential for the cost-effective manufacture of cell and gene therapies. Many of the current production workflows are reliant on basal media in batch-mode, which ...

Transfection techniques are pivotal advances in molecular biology that allow scientists to reliably introduce DNA, RNA, ribonucleoproteins (RNPs), and other molecules into cells. Several delivery ...

This research investigates how to optimize mRNA transfection in human T-cells utilizing the jetMESSENGER ® transfection reagent. By using advanced bioanalytical instruments like the Incucyte ® ...